BiotechTube
Kestrel Therapeutics

Kestrel Therapeutics

Cambridge, United States· Est.
kestreltherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $85M

Overview

Kestrel Therapeutics is a private, clinical-stage biotech founded in 2015 and headquartered in Cambridge, Massachusetts. The company is dedicated to developing best-in-class small molecule inhibitors targeting the KRAS oncogene, one of the most frequently mutated drivers in human cancer. Its core technology aims to potently and selectively inhibit KRAS regardless of mutation or tumor type, with a lead program, KST-6051, now advancing into Phase 1 studies. Kestrel operates as a pre-revenue, therapeutics-focused company targeting a significant unmet need in oncology.

Oncology

Technology Platform

Platform for developing small molecule inhibitors targeting protein-protein interactions, specifically focused on creating pan-KRAS inhibitors active against both the OFF (GDP-bound) and ON (GTP-bound) states of the KRAS protein to durably disrupt oncogenic signaling.

Funding History

2
Total raised:$85M
Series B$60M
Series A$25M

Opportunities

The opportunity lies in addressing the large, underserved patient population with non-G12C KRAS mutations (e.g., G12D, G12V), which are more common in cancers like pancreatic and colorectal.
A successful oral pan-KRAS inhibitor could become a foundational therapy across multiple solid tumor types, representing a multi-billion dollar market opportunity.

Risk Factors

Key risks include the high scientific difficulty of achieving safe and effective pan-KRAS inhibition, intense competition from larger biopharma companies with advanced KRAS programs, and the financial and operational risks associated with being a private, single-asset, early-stage company.

Competitive Landscape

The KRAS competitive landscape is intense, featuring approved G12C-specific drugs (Amgen's Lumakras, Mirati's Krazati) and numerous clinical-stage programs from companies like Revolution Medicines (pan-RAS), BridgeBio, and Boehringer Ingelheim. Kestrel must differentiate its pan-KRAS approach on efficacy, safety, and breadth of mutation coverage.

More companies in Small Molecule Drugs →More companies in United States →